0
New
New
2023
Emphysema Treatment Market

Emphysema Treatment Market

by Medication Type (Bronchodilators, Steroids, Others), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A14372
Pages: 210
Jan 2023 | 923 Views
Author(s) : Swapna S , Onkar S
Tables: 105
Charts: 54
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

Emphysema Treatment Market Research, 2031

The global emphysema treatment market size was valued at $4,474.71 million in 2021 and is projected to reach $7,292.90 million by 2031, growing at a CAGR of 5% from 2022 to 2031. Emphysema is also referred as chronic obstructive disorder because inhalation and exhalation are slowed down due to over inflammation of alveoli. Emphysema can cause damage to air sac which results in change of shape of air sac or often destruction resulting in low gas exchanged in the lungs leading difficulty in breathing. This happens because air is trapped inside alveoli due to its damage results insufficient space for air to enter in the sacs. The emphysema patient can be treated by improving shortness of breath and reducing the number of hospitalizations with bronchodilators and steroids.

The COVID-19 pandemic had a positive impact on the market growth, owing to the increasing demand of drugs used in the treatment of chronic obstructive pulmonary disease in patients infected with COVID-19 infection. The patients that are infected with coronavirus basically suffer from similar symptoms like breathing difficulty, insufficient supply of oxygen rich blood to lungs and overall body as in chronic obstructive pulmonary disease (COPD), thus rise in demand for drugs used in the treatment of chronic obstructive pulmonary disease increased during pandemic.

Emphysema Treatment Market

“The emphysema treatment market was positively impacted during the lockdown period owning to increase in sales of bronchodilators and antibiotics. In addition, increase in demand of steroids for treating chronic obstructive pulmonary disease was observed owing similar symptoms experience in covid patients.”

Historical Overview

The emphysema treatment market size was analyzed qualitatively and quantitatively from 2021-2031. The emphysema treatment market grew at a highest CAGR during 2021-2031. Most of the growth during this period was derived from the Asia-Pacific owing to the owing to factors such as effective distribution network for emphysema treatment drugs, awareness regarding emphysema and treatment related to it in the region.

Market Dynamics

Growth & innovations in the pharmaceutical industry for the manufacturing of emphysema treatment drugs owing to massive pool of health-conscious consumers, creates an opportunity for the emphysema market. Rise in launch of various curative

dual bronchodilators for COPD treatment management, rise in new triple combination of drugs for emphysema by various key players across the globe is set to affect the emphysema treatment market growth positively. For instance, GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration (FDA) approval for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm. The growth of the emphysema treatment market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of COPD cases in adults, and surge in demand for steroidal drugs for management of COPD. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.

Various organizations along with government are counselling people regarding the emphysema. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding chronic obstructive pulmonary disease (COPD) has contributed to growth of this emphysema treatment market share. The demand for effective bronchodilators and steroids is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Factors such as rise in adoption of antibiotics like azithromycin for COPD treatment and increase in awareness toward use of antibiotics and anticholinergics, further drive the growth of the market. Moreover, increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for chronic obstructive pulmonary disease (COPD) among the general population is expected to fuel their adoption in the near future.

However, side effects of the drug used in emphysema treatment restrains the growth of emphysema treatment market. In addition, drug failure of new drugs in clinical trials, also might hinder the growth of market. In contrast, increase in advancements for developing effective medications in combination dosage form for chronic obstructive pulmonary disease (COPD) provide lucrative opportunities to the market players.

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The COVID-19 pandemic had a positive impact on the market growth, owing to the increasing demand of drugs used in the treatment of chronic obstructive pulmonary disease in patients infected with COVID-19 infection. The patients that are infected with coronavirus basically suffer from similar symptoms like breathing difficulty, insufficient supply of oxygen rich blood to lungs and overall body as in chronic obstructive pulmonary disease (COPD), thus rise in demand for drugs used in the treatment of chronic obstructive pulmonary disease increased during pandemic.

Segmental Overview

The emphysema treatment market is segmented into medication type, distribution channel, and region. On the basis of medication type, the market is segregated into bronchodilators, steroids, and others. On the basis of distribution channel, the market is categorized into hospitals pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Emphysema Treatment Market
By Medication Type

Your browser does not support the canvas element.

Others segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Depending on medication type, the market is bifurcated into bronchodilators, steroids, and others (antibiotics & anticholinergics). The bronchodilators segment exhibited highest growth in 2021 and is expected to remain dominant during the emphysema treatment market forecast period, owing to rise in demand of bronchodilators for emphysema treatment and awareness regarding it. In addition, increase in prevalence of COPD cases leads to rise in demand for bronchodilator inhalers which further boost the segment growth.

Emphysema Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Stores and Retail Pharmacies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By distribution channel, the emphysema treatment industry is segmented into hospital pharmacies, online providers, and drug stores & retail pharmacies. The drug stores & retail pharmacies segment exhibited highest growth in 2021, owing to be a standard method of purchasing emphysema medications and is highly favored by the

patients across the globe. However, the online providers segment is projected to register highest CAGR of 6.4% during the forecast period. This is attributed to rise in demand for online providers offering emphysema treatment medications, as it prevents the need to visit hospitals for treatment which boost the market growth.

Emphysema Treatment Market
By Region

2031
North America 
Europe
Asia-Pacific
LAMEA

North America held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region the emphysema treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America had the highest market share in 2021 and is expected to maintain its lead during the forecast period, owing to high incidences of emphysema and rise in spending in health infrastructure. In addition, rise in technological innovations for COPD medications and increase in awareness regarding chronic obstructive pulmonary disease (COPD) further drives the market growth in this region. However, Asia-Pacific is expected to witness highest growth during the forecast period, owing to factors such as rise in investments in manufacturing of high-quality emphysema drugs.

Presence of several major players, such as AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc, and advancement in manufacturing technology for development of effective medications for COPD treatment in the region drive the growth of the market. In addition, various private organizations organize educating camps across the globe marked the growth of this market. In addition, organizations like Reckitt launched new education and early detection campaign for patients with undiagnosed chronic obstructive pulmonary disease (COPD). Furthermore, presence of well-established healthcare infrastructure, and rise in adoption rate of large volume inhalation medications for COPD disorders are expected to drive the market growth. Furthermore, various product approval and contract agreement as key strategy adopted by the key players in this region further boost the growth of the market. For instance, GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

Asia-Pacific expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of key players in the region. Moreover, rise in adoption of various triple combination formulations for emphysema drive the growth of the market. India has highest number of chronic obstructive pulmonary disease (COPD) owing to rise in number of smokers. For instance, according to article published in Lung India 2021, stated that prevalence of chronic obstructive pulmonary disease (COPD) was found to 19% with high cases among males, in the urban area, and the northern region. China has highest people diagnosed with chronic obstructive pulmonary disease (COPD) due high number of smokers, ambient air pollution and unhealthy lifestyle. For instance, according to article published in Frontiers in Public Health 2022, China accounted for almost 25% of all COPD cases globally with 67% rise in COPD cases among people aged 40 years and above. Asia-Pacific offers profitable opportunities for key players operating in the emphysema treatment market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising in spending for lung disorders, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.

Competitive analysis

Competitive analysis and profiles of the major players in the emphysema treatment market, such as AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona pharma. are provided in this report. Major players have adopted product launch, product approval and contract agreement as key developmental strategies to improve the product portfolio of the emphysema treatment market.

Some examples of contract in the market

In December 2019, Highmark and Boehringer Ingelheim today announced a new value-based contract for Boehringer Ingelheim’s Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray for the treatment of chronic obstructive pulmonary disease (COPD). This marks the second value-based contract between the two companies. It is

also the first contract for Highmark to include Medicare plans in addition to commercial health plans.

Product Approval in The Market

In July 2020, AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Product Launches in The Market

In June 2021, Teva Pharmaceutical Industries Ltd., announced its U.S. launch of the first generic version of twice daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2021 to 2031 to identify the prevailing emphysema treatment market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Emphysema Treatment Market Report Highlights

Aspects Details
Market Size By 2031 USD 7.3 billion
Growth Rate CAGR of 5%
Forecast period 2021 - 2031
Report Pages 210
Medication Type
  • Bronchodilators
  • Steroids
  • Others
Distribution Channel
  • Online Providers
  • Drug Stores and Retail Pharmacies
  • Hospital Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Pfizer, Inc., teva pharmaceuticals, orion corporation, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Verona Pharma, Novartis AG, AstraZeneca, Boehringer Ingelheim International GmbH, Mylan Pharmaceuticals ( a subsidiary of Viatris)
 

Loading Table Of Content...


 
 

This section provides various opinions of top-level CXOs in the global emphysema treatment market. According to the insights of CXOs, increase in demand for advanced inhalers for emphysema treatment globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government policies and schemes for development of novel formulations for COPD treatment has piqued the interest of several companies to develop advanced medications.

CXOs further added that increase in chronic obstructive pulmonary disease (COPD) cases in developing regions have largely contributed to the market revenue in 2021 and is expected to maintain this trend throughout the forecast period. In addition, increase in emphysema cases due to alpha-1 antitrypsin deficiency across globe and rise in demand for novel medications in many countries significantly contribute toward the revenue generation.

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness toward emphysema, early diagnosis & treatment, and rise in government initiatives promoting research activities for development of new advanced formulations. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is expected to witness notable growth owing to increase in number of key players manufacturing emphysema drugs and surge in the number of cigarette smokers, leading to rise in cases of COPD diseases during the forecast period.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The upcoming trends of Emphysema Treatment Market in the world rise in number of smokers in many regions and increasing prevalence of chronic obstructive pulmonary disease (COPD).

A. Chronic obstructive pulmonary disease is the leading application of Emphysema Treatment Market.

A. North America is the largest regional market for Emphysema Treatment.

A. Emphysema Treatment market is estimated to reach $7,292.90 million by 2031, exhibiting a CAGR of 5% from 2022 to 2031.

A. Major key players that operate in the global Emphysema treatment market are AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona pharma

A. The base year is 2021 in Emphysema Treatment market

A. Yes, the Emphysema Treatment market report provides PORTER Analysis

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Emphysema Treatment Market

Start reading instantly.
This Report and over 19,654+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2024 - Jan 2025)
  • Library
    Membership

  • $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers